Get started
Madrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

MDGL chart


Full chart

MDGL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.12 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−22.11 USD
Net income (FY)
‪−465.89 M‬ USD
Revenue (FY)
‪180.13 M‬ USD
Shares float
‪19.95 M‬
Beta (1Y)
0.37

Employees


Employees (FY)
528
Change (1Y)
+152 +40.43%
Revenue / Employee (1Y)
‪341.16 K‬ USD
Net income / Employee (1Y)
‪−882.37 K‬ USD

About Madrigal Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
William J. Sibold
Website
madrigalpharma.com
Headquarters
West Conshohocken
Founded
2000
FIGI
BBG000QS6NV8
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MDGL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as MDGL.

Frequently Asked Questions


The current price of MDGL is 321.10 USD — it has decreased by −1.77% in the past 24 hours. Watch Madrigal Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Madrigal Pharmaceuticals, Inc. stocks are traded under the ticker MDGL.
MDGL stock has fallen by −2.17% compared to the previous week, the month change is a −3.61% fall, over the last year Madrigal Pharmaceuticals, Inc. has showed a 35.49% increase.
We've gathered analysts' opinions on Madrigal Pharmaceuticals, Inc. future price: according to them, MDGL price has a max estimate of 544.00 USD and a min estimate of 239.00 USD. Watch MDGL chart and read a more detailed Madrigal Pharmaceuticals, Inc. stock forecast: see what analysts think of Madrigal Pharmaceuticals, Inc. and suggest that you do with its stocks.
MDGL reached its all-time high on Jan 29, 2013 with the price of 415.38 USD, and its all-time low was 5.24 USD and was reached on Feb 8, 2016. View more price dynamics on MDGL chart.
See other stocks reaching their highest and lowest prices.
MDGL stock is 5.05% volatile and has beta coefficient of 0.37. Track Madrigal Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Madrigal Pharmaceuticals, Inc. there?
Today Madrigal Pharmaceuticals, Inc. has the market capitalization of ‪7.12 B‬, it has decreased by −4.15% over the last week.
Yes, you can track Madrigal Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Madrigal Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
MDGL earnings for the last quarter are −2.71 USD per share, whereas the estimation was −3.92 USD resulting in a 30.86% surprise. The estimated earnings for the next quarter are −3.74 USD per share. See more details about Madrigal Pharmaceuticals, Inc. earnings.
Madrigal Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪103.32 M‬ USD, despite the estimated figure of ‪99.09 M‬ USD. In the next quarter, revenue is expected to reach ‪113.69 M‬ USD.
MDGL net income for the last quarter is ‪−59.42 M‬ USD, while the quarter before that showed ‪−106.96 M‬ USD of net income which accounts for 44.45% change. Track more Madrigal Pharmaceuticals, Inc. financial stats to get the full picture.
No, MDGL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 528 employees. See our rating of the largest employees — is Madrigal Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Madrigal Pharmaceuticals, Inc. EBITDA is ‪−496.78 M‬ USD, and current EBITDA margin is −275.78%. See more stats in Madrigal Pharmaceuticals, Inc. financial statements.
Like other stocks, MDGL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Madrigal Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Madrigal Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Madrigal Pharmaceuticals, Inc. stock shows the buy signal. See more of Madrigal Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.